✓Sep 16 session - Last update: Sep 16, 2026, 4:42 PM ET
🛡Material / Earnings✓High confidence
Source: daily_prices:fmp_change_percent
Changes History →Pre-market · Regular session opens 9:30 AM ET
Last update: Sep 16, 2026, 5:08 PM ETMarket closed·110 changes confirmed today
Track the stock moves that actually matter.
BestStocks detects meaningful changes across price, volume, earnings, filings, valuation, analyst revisions, and risk signals — and shows you the evidence behind each one.
1,000 equities monitored14 signal typesCross-checked against SEC EDGARMedian detection lag ~41s
Investment research built around change detection.
Showing:
BestStocks identifies what changed across companies and sectors, explains why it matters, and helps investors spot opportunities worth investigating.
✓Sep 16 session - Last update: Sep 16, 2026, 4:57 PM ET
🛡Material / Earnings✓High confidence
What changed: Matador Resources Company (MTDR) moved -6.42% from $61.69 to $57.73 on September 16, 2026. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average at 1.1x, indicating the move occurred without unusual trading activity.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
MTDR earnings report expected October 27, 2026.
✓Sep 16 session - Last update: Sep 16, 2026, 4:53 PM ET
🛡Material / Earnings✓High confidence
What changed: Chime Financial, Inc. Class A Common Stock (CHYM) moved -6.32% from $33.36 to $31.25 on 2026-09-16. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move coincided with CHYM reaching a new 30-day low; volume was near its 5-day average.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
CHYM earnings are scheduled for 2026-11-04 with a consensus EPS estimate of $0.06.
✓Sep 16 session - Last update: Sep 16, 2026, 4:52 PM ET
⚡Material / Earnings✓High confidence
What changed: TG Therapeutics, Inc. (TGTX) moved +5.14% from $53.12 to $55.85 on 2026-09-16. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was 1.6x the 5-day average, modestly elevated.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
TGTX earnings report expected 2026-11-02.
✓Sep 16 session - Last update: Sep 16, 2026, 4:52 PM ET
🛡Material / Earnings✓High confidence
What changed: Range Resources Corporation (RRC) moved -5.99% from $41.33 to $38.85 on 2026-09-16, reaching a new 30-day low. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move occurred on modestly elevated volume (1.4x the 5-day average) with no identified trigger.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Range Resources' Q3 earnings on 2026-10-27 against the $0.81 consensus estimate.
✓Sep 16 session - Last update: Sep 16, 2026, 4:51 PM ET
⚡Material / Earnings✓High confidence
What changed: Bruker Corporation (BRKR) moved +7.12% to $60.67 on September 16, 2026, after management presented at the Morgan Stanley 24th Annual Global Healthcare Conference, highlighting a forward-looking strategy focused on post-genomic growth in proteomics and spatial biology. The move also reflected investor momentum from the recent announcement that Bruker Energy & Supercon Technologies (BEST) partnered with Luvata to scale up RRP superconductor manufacturing for next-generation magnetic confinement fusion projects, and followed a recent UBS price target raise to $65.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Earnings scheduled for November 2, 2026 (consensus EPS: $0.42) will test whether management's forward guidance and fusion-energy partnership translate into revised 2026–2027 guidance.
✓Sep 16 session - Last update: Sep 16, 2026, 4:50 PM ET
🛡Material / Earnings✓High confidence
What changed: Hecla Mining Company (HL) moved -5.76% from $19.09 to $17.99 on 2026-09-16. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
HL earnings scheduled for 2026-11-04 with consensus EPS estimate of $0.17.
✓Sep 16 session - Last update: Sep 16, 2026, 4:50 PM ET
🛡Material / Earnings✓High confidence
What changed: Coeur Mining, Inc. (CDE) moved −6.69% from $20.34 to $18.98 on September 16, 2026, as part of a broader profit-taking cycle following a 30% surge over the preceding month. The decline reflects cooling momentum after the stock peaked near $21–$22 in late August, with choppy precious metals sentiment and active traders locking in gains after the company's record Q2 earnings and revenues topping $1 billion.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
CDE earnings scheduled for November 4, 2026 (date not yet confirmed), with consensus EPS estimate of $0.24.
✓Sep 16 session - Last update: Sep 16, 2026, 4:42 PM ET
🛡Material / Earnings✓High confidence
What changed: Roblox Corporation (RBLX) moved -5.35% from $50.11 to $47.43 on 2026-09-16. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, suggesting the decline occurred without unusual trading activity.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Monitor for earnings release on or around 2026-10-29 and any pre-announcement updates.
✓Sep 16 session - Last update: Sep 16, 2026, 4:41 PM ET
⚡Material / Earnings✓High confidence
What changed: Edwards Lifesciences Corporation (EW) moved +5.05% from $84.99 to $89.28 on September 16, 2026, driven by expanded Medicare coverage for TAVR (transcatheter aortic valve replacement) procedures to asymptomatic patients and management presentations at the Deutsche Bank 2026 Healthcare Summit.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
EW earnings scheduled for October 29, 2026 (consensus EPS estimate: $0.73).
✓Sep 16 session - Last update: Sep 16, 2026, 4:57 PM ET
⚡Material / Earnings✓High confidence
What changed: Commvault Systems, Inc. (CVLT) moved +2.68% from $141.42 to $145.21 on 2026-09-16, reaching a new 30-day high. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move appears to be technically driven, with the stock reaching a new 30-day high on near-average volume.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
CVLT earnings on 2026-10-27 (consensus EPS $1.25) — watch for whether the stock sustains above $145 or pulls back ahead of the print.
✓Sep 16 session - Last update: Sep 16, 2026, 4:57 PM ET
🛡Material / Earnings✓High confidence
What changed: Noble Corporation Plc (NE) moved -3.94% from $46.16 to $44.34 on 2026-09-16. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, indicating the move was not driven by unusual trading activity.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Monitor Noble's Q3 2026 earnings release on 2026-10-26 to assess whether operational or financial performance justified the prior decline.
Latest research
View all research →In-depth equity research from the BestStocks desk — earnings breakdowns, valuation deep dives, and sector analysis behind the changes we detect.
Stock AnalysisSeptember 16, 2026 · 9 min read
Intel (INTC) Jumps on a Report SK Hynix May Make Memory at Its Delayed Ohio Fab
Intel rose about 4% to roughly $101 on September 16 after Reuters reported, citing sources, that SK Hynix is in early talks to manufacture memory chips in the United States for the first time — possibly by leasing part of Intel's long-delayed Ohio megafab, or through a joint venture with Intel and cloud hyperscalers. Crucially, no deal is confirmed: the shares spiked toward +6% then pared to +4% as SK Hynix said nothing had been decided and Intel declined to comment, so the honest read is a market pricing a possibility. It matters because Intel's Ohio project — announced in 2022 and delayed roughly five to six years (construction now finishing around 2030–2031) — could turn from a symbol of the company's troubles into a proof point if a marquee partner pays to use it. The move landed on a stock already up roughly 300% over the past year, still unprofitable on a trailing GAAP basis and trading near 66 times its fiscal-2026 adjusted (non-GAAP) earnings estimate, so it trades on narrative — and chips were broadly higher on the day, meaning only part of the pop was Intel-specific.
INTCRead →
Stock AnalysisSeptember 15, 2026 · 9 min read
Sysco (SYY) Falls ~4% as It Prices a $1 Billion Stock Sale to Help Fund Its $29 Billion Jetro Deal
Sysco fell about 4.4% to roughly $80 on September 15 after pricing a $1.0 billion common-stock offering at $81.00 a share — below the prior close — to help fund the cash portion of its pending, roughly $29 billion acquisition of Jetro Restaurant Depot. The stock did what freshly issued equity often does, drifting toward and then below the offer price. One honest caveat: this was not a Sysco-only move — direct peers US Foods (−4.4%) and Performance Food Group (−3.8%) fell just as hard, while consumer staples barely budged, so the raise is best read as the trigger inside a wider foodservice-distribution derating. The $1 billion is the equity slice of a mostly debt-funded deal (~$21 billion of new borrowings), issued to limit the added leverage and defend an already-levered balance sheet; the larger dilution is the 91.5 million new shares (about 19% as the March terms estimated) still to go to Jetro's owners. Sysco is a defensive Dividend King trading near 16 times forward earnings, and the Street's targets still sit above the price — but the market wants the transformational deal financed and integrated before it re-rates.
SYYRead →
Stock AnalysisSeptember 15, 2026 · 9 min read
Axon (AXON) Drops ~9% on a $1 Billion 0% Convertible Notes Offering
Axon Enterprise fell about 9% to roughly $447 on September 15 after announcing a $1.0 billion offering of 0% convertible senior notes due 2031 — a financing event, not a business stumble. The counterintuitive drop on interest-free borrowing is a lesson in how markets price equity-linked debt: convertible notes can turn into shares, so the market immediately prices the potential dilution overhang, and the hedge funds that buy converts typically short the stock to hedge, which tends to add mechanical selling pressure around a deal. Axon is buying capped calls to blunt the dilution and earmarking the rest for acquisitions. The drop landed on a stock already down about 41% from its 2025 high and trading near 50 times forward earnings despite ~35% revenue growth — a de-rated compounder now using its shares as funding currency. The move was starkly company-specific: closest peer Motorola Solutions fell under 1%, Palantir rose, and the S&P 500 barely moved, while the Street's price targets still cluster far above the price.
AXONRead →
TechnologySeptember 9, 2026 · 8 min read
Meta (META) Jumps as Muse, Its First Paid Personal AI Agent, Puts a Price on AI
Meta rose about 6% to roughly $650 on September 9 after launching Muse, a personal AI agent — and, crucially, attaching a price to it: a free tier plus subscriptions at $20 and $100 a month. For a company that has spent enormous sums building AI infrastructure with little consumer revenue to show for it, Muse is a major new consumer-AI monetization line — its first paid personal-agent product — the proof of concept investors had been waiting for. Muse is an autonomous assistant that reads email, books travel, negotiates, and makes purchases through connected payment systems, rolling out in the US on iOS, Android and the web. The launch also rippled across the mega-caps: Alphabet fell ~2.6% as a capable buying-and-booking agent was read as a competitive threat to Google's search (Amazon also slipped ~2.1%, though it had its own news that day). The context is that Meta had lagged — down ~13% over the past year on AI-cost fears — despite an 82% gross margin, ~28% revenue growth and ~$41 billion of free cash flow, at just 19 times forward earnings. Muse does not resolve the spend-versus-return debate, but it reframes it, and the Street stays overwhelmingly bullish, with an average target implying ~16% upside.
METARead →
HealthcareSeptember 8, 2026 · 9 min read
Amgen (AMGN) Falls as a Rival's Lp(a) Trial Failure Clouds Its Pipeline
Amgen fell about 8% to roughly $404 on September 8 even as it posted its own good news that morning — its cancer drug IMDELLTRA, with AstraZeneca's Imfinzi, hit its primary survival goal in a Phase III lung-cancer study. The shares dropped anyway, on a rival's failure: Novartis disclosed late last week that pelacarsen — its drug for lowering lipoprotein(a), or Lp(a), a genetic cardiovascular risk factor — failed the primary goal of its large Phase III outcomes trial, not reducing heart attacks, strokes and cardiovascular deaths despite lowering Lp(a). Because Amgen is racing in the same class with its own experimental drug, olpasiran, the read-through was direct: the first dedicated Phase III cardiovascular-outcomes readout of an Lp(a) therapy came up empty, casting doubt on the science behind the category. A separate same-day BMO Capital downgrade — on valuation and pipeline grounds — formed part of the negative backdrop. What cushioned the fall is that Amgen is a cheap, cash-rich defensive franchise — about 18 times forward earnings, a 2.5% dividend, ~$10 billion of free cash flow — so the Lp(a) opportunity was upside, not the foundation. Even so, the stock had run up ~43% over the year, and the Street was already cautious, with a large share of analysts at Hold and an average target below the pre-drop price.
AMGNRead →
TechnologySeptember 8, 2026 · 8 min read
Intel (INTC) Jumps on a High-NA EUV Milestone, Ahead of TSMC in Deployment
Intel rose about 8% to roughly $103 on September 8 after it and lithography partner ASML announced they have processed more than one million wafers using High-NA EUV — the newest, most advanced chipmaking lithography, by industry accounts more than any rival has run. Intel is deploying the technology on select layers of certain 18A products (chips such as Panther Lake), and reports throughput and yields meeting expectations, giving it a multi-year lead in High-NA production experience — TSMC is generally expected to bring High-NA into high-volume production around 2030, and Samsung targets it for DRAM around 2028. The milestone was the headline, though the stock also had a same-day analyst upgrade and reports of possible processor price increases. For a company whose whole case rests on rebuilding a credible foundry business, it was tangible proof the turnaround is producing real capability. The move caps a staggering ~322% one-year run — yet the fundamentals lag: Intel is still GAAP-unprofitable, and the Street stays cautious, with a Hold consensus (roughly two-thirds of covering analysts on the sidelines) and an average target only about 12% above the price. One firm (Northland) upgraded to Buy on the news; most are waiting for the manufacturing lead to become profit.
INTCRead →